Another randomized, blinded study with patients with non-small-cell lung cancer (NSCLC) (n = 124) showed effectiveness in reducing anemia and CAC after treatment with ALD518, an anti-IL-6 antibody [33]. Here, IL6 is linked to anemia (phenotype).